Use of aripiprazole for psychosis and agitation in dementia.
We report the case of an elderly woman with Alzheimer's disease, risk factors for vascular dementia, and atrium-ventricular blockade, who presented with severe agitation and psychosis. She was treated with aripiprazole and assessed with the Neuropsychiatric Inventory (NPI) over the course of 14 weeks. NPI scores showed a marked decrease in psychosis and agitation at week 4, and complete recovery at week 14, except for depression.
Laks
Jerson
J
Center for Alzheimer's Disease and Related Disorders, Institute of Psychiatry, Federal University of Rio de Janeiro, RJ, Brazil. jlaks@centroin.com.br
Miotto
Roberto
R
Marinho
Valeska
V
Engelhardt
Eliasz
E
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D005260:Female; D006801:Humans; D009483:Neuropsychological Tests; D010879:Piperazines / Q000627:therapeutic use*; D011595:Psychomotor Agitation / Q000188:drug therapy; D011618:Psychotic Disorders / Q000188:drug therapy*; D015363:Quinolones / Q000627:therapeutic use*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole